French drugmaker Sanofi (Euronext: SAN) is searching for a new global head of R&D after the role’s current incumbent John Reed announced he was off to pursue an undisclosed opportunity outside the company.
Since joining Sanofi in 2018, Dr Reed is credited for laying the foundation for the company’s R&D transformation, helping to reshape the group’s discovery and development of therapeutics and focusing efforts on first and best in class medicines, while managing the integration and development of new technology platforms and partnerships, and driving R&D productivity.
While an internal and external search has already started to identify the successor to Dr Reed, Dietmar Berger, has agreed to take the leadership of the team ad interim.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze